Trial · NCT02005029

Erythromycin in Parkinson's Disease

NCT02005029, Not applicable, Completed, Virginia Commonwealth University; results first posted 2017-02-03

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Erythromycin in Parkinson's Disease. Trials, record NCT02005029. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02005029

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Erythromycin in Parkinson's Disease
NCT number: NCT02005029
Status: Completed
Phases: Not applicable
Enrollment: 18 participants, actual
Lead sponsor: Virginia Commonwealth University
Conditions: Parkinson's Disease, Levodopa
Interventions: Erythromycin, placebo
First posted: 2013-12-09
Last updated: 2017-02-03
Results first posted: 2017-02-03
Limitations and caveats: An overall limitation was the small sample size.

Source ClinicalTrials.gov

Registered outcomes11

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Gastric Emptying Time	2 weeks, between visits 2 and 3	Mean gastric emptying time in minutes as measured by SmartPill
Primary	Area Under the Curve 0-4 Hours for Plasma Levodopa After Erythromycin Versus Placebo	2 weeks, between visits 2 and 3	Mean Area under the Curve 0-4 hours for plasma levodopa after erythromycin versus placebo. Plasma samples were collected at the following times post-levodopa dose: 15, 30, 45, 60, 75, 90, 105, 120, 150, 180, 210, and 240 minutes.
Secondary	9-hole Peg Test Right Hand	2 weeks, between visits 2 and 3	Change in motor function as assessed by 9-hole peg test for upper extremity manipulation/dexterity. This test measures the total time required to place and remove 9 holes in a pegboard. Each hand is tested separately.
Secondary	9-hole Peg Test Left Hand	2 weeks, between visits 2 and 3	Change in motor function as assessed by 9-hole peg test for upper extremity manipulation/dexterity. This test measures the total time required to place and remove 9 holes in a pegboard. Each hand is tested separately.
Secondary	Five Times Sit-to-stand Test	2 weeks, between visits 2 and 3	Change in motor function as measured by Five times sit-to-stand test. This test measures the total time to complete 5 repetitions of sit to stand.
Secondary	Comfortable 20 Feet Gait Speed (CGS)	2 weeks, between visits 2 and 3	Change in motor function as assessed by comfortable 20 feet gait speed (CGS)
Secondary	Timed up and go Test (TUAG) Comfortable Speed	2 weeks, between visits 2 and 3	Change in motor function as assessed by timed up and go test (comfortable speed). This test measures the total time to stand from a chair, walk 10 feet, and return to sitting.
Secondary	Timed up and go Test (TUAG) Fast Speed	2 weeks, between visits 2 and 3	Change in motor function as assessed by timed up and go test (fast speed). This test measures the total time to stand from a chair, walk 10 feet, and return to sitting.
Secondary	Change in Dyskinesia	2 weeks, between visits 2 and 3	Mean total AIMS (Abnormal Involuntary Movements Scale) score after receiving erythromycin minus mean total AIMS score after receiving placebo. The AIMS test has a total of twelve items rating involuntary movements of various areas of the patient's body. Ten of the items are rated on a five-point scale of severity from 0-4. The scale is rated from 0 (none), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe). Two of the items are not scored. Total score range is from 0 to 40. Higher scores represent more severe dyskinesia (a worse outcome).
Secondary	MDS-UPDRS Part 3 (Movement Disorders Society- Unified Parkinson's Disease Rating Scale)	2 weeks, between visits 2 and 3	Part 3 of this scale is a standardized physical assessment that quantifies the total burden of motor symptoms in Parkinson's disease patients. Each of the 18 items on the scale is rated from 0 (none, 1 (slight), 2 (mild), 3 (moderate) and 4 (severe). Scores range from 0-72. Higher scores represent a more severe burden of motor symptoms (a worse outcome).

1 to 10 of 11Source ClinicalTrials.gov

See all 11 registered outcomes

Outcomes11

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Gastric Emptying Time	2 weeks, between visits 2 and 3	Of the original ten participants; one participant's data was excluded due to symptomatic orthostasis which likely confounded her results, one participant was withdrawn early due to noncompliance, and four participants were unable to complete a SmartPill evaluation.	minutes	MEAN
PRIMARY	Area Under the Curve 0-4 Hours for Plasma Levodopa After Erythromycin Versus Placebo	2 weeks, between visits 2 and 3	Of the original ten participants; one participant's data was excluded due to symptomatic orthostasis which likely confounded her results, one participant was withdrawn early due to noncompliance, and one participant had undetectable plasma levodopa levels through out the study and was thus excluded from the pharmacokinetic analysis.	ng/mL*min	MEAN
SECONDARY	9-hole Peg Test Right Hand	2 weeks, between visits 2 and 3	Of the original 10 participants, one participant's data was excluded due to symptomatic orthostasis which likely confounded her results and one participant was withdrawn early due to noncompliance.	seconds	MEAN
SECONDARY	9-hole Peg Test Left Hand	2 weeks, between visits 2 and 3	Of the original 10 participants, one participant's data was excluded due to symptomatic orthostasis which likely confounded her results and one participant was withdrawn early due to noncompliance.	seconds	MEAN
SECONDARY	Five Times Sit-to-stand Test	2 weeks, between visits 2 and 3	Of the original 10 participants, one participant's data was excluded due to symptomatic orthostasis which likely confounded her results and one participant was withdrawn early due to noncompliance.	seconds	MEAN
SECONDARY	Comfortable 20 Feet Gait Speed (CGS)	2 weeks, between visits 2 and 3	Of the original 10 participants, one participant's data was excluded due to symptomatic orthostasis which likely confounded her results and one participant was withdrawn early due to noncompliance.	seconds	MEAN
SECONDARY	Timed up and go Test (TUAG) Comfortable Speed	2 weeks, between visits 2 and 3	Of the original 10 participants, one participant's data was excluded due to symptomatic orthostasis which likely confounded her results and one participant was withdrawn early due to noncompliance.	seconds	MEAN
SECONDARY	Timed up and go Test (TUAG) Fast Speed	2 weeks, between visits 2 and 3	Of the original 10 participants, one participant's data was excluded due to symptomatic orthostasis which likely confounded her results and one participant was withdrawn early due to noncompliance.	seconds	MEAN
SECONDARY	Change in Dyskinesia	2 weeks, between visits 2 and 3	Of the original 10 participants, one participant's data was excluded due to symptomatic orthostasis which likely confounded her results and one participant was withdrawn early due to noncompliance.	units on a scale	MEAN
SECONDARY	MDS-UPDRS Part 3 (Movement Disorders Society- Unified Parkinson's Disease Rating Scale)	2 weeks, between visits 2 and 3	One participant's data was excluded due to symptomatic orthostasis which likely confounded her results and one participant was withdrawn early due to noncompliance.	units on a scale	MEAN

1 to 10 of 11Source ClinicalTrials.gov

See all 11 outcomes

Results by group24

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Gastric Emptying Time	Erythromycin	105	Standard Deviation 66.5	minutes
Gastric Emptying Time	Placebo	180	Standard Deviation 40.6	minutes
Area Under the Curve 0-4 Hours for Plasma Levodopa After Erythromycin Versus Placebo	Erythromycin	123237	Standard Deviation 137561	ng/mL*min
Area Under the Curve 0-4 Hours for Plasma Levodopa After Erythromycin Versus Placebo	Placebo	103584	Standard Deviation 106271	ng/mL*min
9-hole Peg Test Right Hand	Erythromycin	25.36	Standard Deviation 4.37	seconds
9-hole Peg Test Right Hand	Placebo	25.80	Standard Deviation 4.23	seconds
9-hole Peg Test Left Hand	Erythromycin	29.36	Standard Deviation 6.27	seconds
9-hole Peg Test Left Hand	Placebo	27.33	Standard Deviation 6.45	seconds
Five Times Sit-to-stand Test	Erythromycin	11.09	Standard Deviation 2.24	seconds
Five Times Sit-to-stand Test	Placebo	10.09	Standard Deviation 2.48	seconds

1 to 10 of 24Source ClinicalTrials.gov

See all 24 results by group

Participant flow18

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
First Intervention (1 Day)	STARTED	Placebo First Then Erythromycin	5
First Intervention (1 Day)	STARTED	Erythromycin Then Placebo	5
First Intervention (1 Day)	COMPLETED	Placebo First Then Erythromycin	4
First Intervention (1 Day)	COMPLETED	Erythromycin Then Placebo	5
First Intervention (1 Day)	NOT COMPLETED	Placebo First Then Erythromycin	1
First Intervention (1 Day)	NOT COMPLETED	Erythromycin Then Placebo	0
Washout (2 Weeks)	STARTED	Placebo First Then Erythromycin	4
Washout (2 Weeks)	STARTED	Erythromycin Then Placebo	5
Washout (2 Weeks)	COMPLETED	Placebo First Then Erythromycin	4
Washout (2 Weeks)	COMPLETED	Erythromycin Then Placebo	5

1 to 10 of 18Source ClinicalTrials.gov

See all 18 participant flow

Adverse events10

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	symptomatic orthostasis	Cardiac disorders	Erythromycin	1	9	1
other	symptomatic orthostasis	Cardiac disorders	Placebo	1	10	1
other	akathisia	Nervous system disorders	Erythromycin	1	9	1
other	akathisia	Nervous system disorders	Placebo	0	10	0
other	diarrhea	Gastrointestinal disorders	Erythromycin	1	9	1
other	diarrhea	Gastrointestinal disorders	Placebo	0	10	0
other	possible hematuria	Renal and urinary disorders	Erythromycin	1	9	1
other	possible hematuria	Renal and urinary disorders	Placebo	0	10	0
other	transaminitis	Hepatobiliary disorders	Erythromycin	0	9	0
other	transaminitis	Hepatobiliary disorders	Placebo	1	10	1

Source ClinicalTrials.gov

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Erythromycin
Total, all-cause mortality	Placebo
Total, other adverse events	Erythromycin	4	9
Total, other adverse events	Placebo	2	10
Total, serious adverse events	Erythromycin	0	9
Total, serious adverse events	Placebo	0	10

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons1

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison
Erythromycin vs Placebo: serious adverse events

Source Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02005029

GET https://conductscience.org/api/trials/v1/NCT02005029/results?page=2

API reference For AI assistants